Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 12th, 2021

Daniel J. Rader, MD, to receive AHA’s 2021 Research Achievement Award

The Research Achievement Award is the association’s highest scientific award, given each year in recognition of outstanding lifetime contributions to cardiovascular research and/or teaching.


Daniel J. Rader, MD, FAHA
Daniel J. Rader, MD, FAHA

Daniel J. Rader, MD, FAHA, of the Perelman School of Medicine at the University of Pennsylvania, was named the recipient of the 2021 Research Achievement Award. 

The Research Achievement Award is the association’s highest scientific award, given each year in recognition of outstanding lifetime contributions to cardiovascular research and/or teaching. Dr. Rader’s outstanding lifetime contributions to basic and translational research in the genetics and pathophysiology of lipid disorders have advanced our understanding of the molecular regulation of lipoprotein metabolism and the development of therapies for dyslipidemia. His research has used genetics and physiology in humans and focused on novel pathways regulating lipid and lipoprotein metabolism and atherosclerosis using genetics, and factors regulating the structure and function of high-density lipoproteins and reverse cholesterol transport.  

Dr. Rader uses a variety of translational approaches to ensure human and clinical relevance to prevent cardiovascular disease. His lab at the Perelman School of Medicine at the University of Pennsylvania integrates “big human data science,” targeted deep phenotyping in selected human subjects, and fundamental, mechanistic investigation in model systems to ensure bidirectional translation of research insights. Dr. Rader has broad expertise across these diverse domains, and he is one of only a few scientists who has integrated these domains to accelerate discovery. During his outstanding career, he has mapped genetic loci and then utilized functional genomics to learn more about the biologic components of these loci to increase understanding of the molecular architecture associated with metabolic traits. As a translational accomplishment, he rescued and developed a microsomal transfer protein inhibitor that received FDA approval for use in patients with homozygous familial hypercholesterolemia.  

“I’m tremendously honored to be recognized by the AHA with the 2021 Research Achievement Award,” said Dr. Rader. “I have committed my career to research, investigating the fundamental basis of lipid disorders and atherosclerotic cardiovascular disease and translating that information into how we can manage and prevent these conditions more effectively. Ensuring that knowledge gleaned from research is used to develop new approaches to unmet medical needs provides scientists like me great incentive, hoping to continue improving patient care and patient outcomes. The greatest achievement in medicine is to contribute to our constantly evolving understanding of the complexities of human health and disease. I’m proud of my research contributions to not only science but also to cardiovascular care and prevention.” 

Dr. Rader, trained and board certified in internal medicine, is the Seymour Gray Professor of Molecular Medicine, chair of the department of genetics, and chief of the division of translational medicine and human genetics in the department of medicine at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia. Dr. Rader directs the Penn Medicine BioBank and serves as associate director of the Institute of Translational Medicine the Therapeutics at Penn, as well as the chief of the division of human genetics at the Children’s Hospital of Philadelphia.  

Dr. Rader earned his medical degree from the Medical College of Pennsylvania. He completed his internship and residency in internal medicine at Yale-New Haven Hospital, and his fellowship at the Molecular Disease Branch of the National Heart, Lung, and Blood Institute of the National Institutes of Health, where he also served as a staff scientist in the Molecular Disease Branch until 1993. He joined the University of Pennsylvania in 1994 as an assistant professor in medicine.  

Dr. Rader has authored more than 600 research papers published in peer-reviewed journals. Dr. Rader has been honored by the association twice before — in 2000 as an Established Investigator awardee and in 2012 with the Clinical Research Prize in recognition of his work to develop new methods of identifying factors that regulate fat metabolism within the bloodstream and testing its impact on the development of atherosclerosis.  

 

Interesting Stories
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
More Content
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021